Juniper pharmaceuticals inc stock

Juniper Pharmaceuticals, a specialty pharmaceutical company focused on addressing unmet medical needs in women's health, will move from its current 

Aug 20, 2018 Catalent expects to complete the merger of Catalent Boston into Juniper under Section 251(h) of the Delaware General Corporation Law on  View the latest Eagle Pharmaceuticals Inc. (EGRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Juniper Pharmaceuticals, a specialty pharmaceutical company focused on addressing unmet medical needs in women's health, will move from its current  Intercept Pharmaceuticals, Inc. Common Stock (ICPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The company also manages the Crinone (progesterone gel) franchise. Catalent has a market cap of $5.6 billion. Juniper's shares shot up 31% in pre-market 

View the latest Eagle Pharmaceuticals Inc. (EGRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

5 stocks under $10 set to soar. By Roberto Pedone. Jan 14, 2016 6:48 AM EST. Analysts' Actions -- Buffalo Wild Wings, Intuit, Monro Muffler, JM Smucker. Real-time trade and investing ideas on Juniper Pharmaceuticals JNP from the largest community of traders and investors. Jul 5, 2018 Juniper Pharmaceuticals (Nasdaq: JNP) has entered into a definitive Juniper is a diversified healthcare company with core businesses of its Crinone News Catalent announces secondary public offering of common stock. Aug 14, 2018 Juniper Pharmaceuticals will become a wholly owned subsidiary of Catalent [ Catalent] and the shares of common stock of Juniper will cease to be traded on As Juniper's parent company, Catalent will continue to supply  Nov 14, 2019 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. of Eyepoint Pharmaceutical's Board of Directors granted stock options to 

Nov 14, 2019 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. of Eyepoint Pharmaceutical's Board of Directors granted stock options to 

Nov 14, 2019 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. of Eyepoint Pharmaceutical's Board of Directors granted stock options to  Nov 14, 2019 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. of Eyepoint Pharmaceutical's Board of Directors granted stock options to  PIRS | Complete Pieris Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Aug 20, 2018 Catalent expects to complete the merger of Catalent Boston into Juniper under Section 251(h) of the Delaware General Corporation Law on  View the latest Eagle Pharmaceuticals Inc. (EGRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Juniper Pharmaceuticals, a specialty pharmaceutical company focused on addressing unmet medical needs in women's health, will move from its current  Intercept Pharmaceuticals, Inc. Common Stock (ICPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Juniper Pharmaceuticals, a specialty pharmaceutical company focused on addressing unmet medical needs in women's health, will move from its current 

Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in   Jul 3, 2018 PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), offer to acquire all of the outstanding shares of Juniper's common stock at a 

PIRS | Complete Pieris Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Juniper Pharmaceuticals, Inc. (JNP). YHD - YHD Delayed Price. Currency in USD . Jul 3, 2018 U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash. Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in   Jul 3, 2018 PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), offer to acquire all of the outstanding shares of Juniper's common stock at a 

PIRS | Complete Pieris Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Aug 20, 2018 Catalent expects to complete the merger of Catalent Boston into Juniper under Section 251(h) of the Delaware General Corporation Law on  View the latest Eagle Pharmaceuticals Inc. (EGRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.